Brief: MHRA Says Licensed Brensocatib as First Drug for Non-Cystic Fibrosis Bronchiectasis in Patients Aged 12+
23/02/2026 09:35
Feb 23 (Reuters) - MHRA: MHRA: BRENSOCATIB LICENSED AS FIRST MEDICINE SPECIFICALLY DESIGNED TO TREAT NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS AND OLDER Source text: [ID:] Further company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Insmed
See all newsAstera Labs, CoreWeave and others rise after Nasdaq-100 inclusion
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings